Eli Lilly agrees to acquire Verve Therapeutics for $1 billion, starting tender offer
MLex Summary: Indianapolis-based Eli Lilly will acquire Boston-based Verve Therapeutics, a clinical-stage company developing genetic medicines for cardiovascular disease. Under the terms of the agreement, Lilly will commence a tender offer to...To view the full article, register now.
Already a subscriber? Click here to view full article